APTAMER GROUP LTD LS-,001 Aktie

Aptamer Group reports a 27% revenue increase in the first half versus the prior year, driven by new and recurring service contracts with pharmaceutical companies, including an order in radioligand therapy. Adjusted EBITDA loss narrowed to £1.0m, gross profit was £0.46m and EBIT stood at −£1.24m. Aptamer received initial licence payments from Twist Bioscience and Alphazyme, is conducting further licence negotiations and aims to convert its asset portfolio into recurring licence and royalty revenues. The company has launched an accelerated bookbuilding to raise at least £3.75m, expects this to provide a cash runway to 2028, and plans to generate in vivo data for the radiopharmaceutical pipeline by the end of 2026 while increasing production capacity and quality audits. » Plus sur de.investing.com

Aptamer Group reports revenue of £0.83m (+27%) for the six months to 31 December 2025 and an adjusted EBITDA loss that narrowed from £1.1m to £1.0m. Cash at 31 December 2025 stood at £1.5m after a £1.8m capital raise in July 2025. In the reporting period the company signed licensing agreements with Twist Bioscience and Alphazyme, received orders including a radioligand therapy order worth £360,000 and further orders totalling £769,000. After the period end Aptamer launched an accelerated bookbuild to raise at least £3.75m to fund asset development and secure liquidity through 2028. » Plus sur de.investing.com

Aptamer Group reports the on-time, on-budget completion of the first phase of its joint project with Metir to develop high-affinity Optimer binders for the rapid detection of Cryptosporidium parvum in water. The feasibility study revealed no technical obstacles, allowing Aptamer to move into phase 2 and target market readiness of the Optimer by Q2 2026. Metir plans, subject to successful validation, a prototype for field testing in H2 2026 and a possible commercial launch in early 2027. Market analyses point to expected growth of the diagnostic market for Cryptosporidium tests from around USD 1.2 billion (2024) to USD 2.5 billion by 2033. » Plus sur de.investing.com